Trailblazing in the Arabian Desert: MyHeritage Sponsors Team Competing in 2021 Dakar Rally
5.1.2021 16:00:00 EET | Business Wire | Press release
MyHeritage, the leading global platform for discovering your past and empowering your future, announced today that it is sponsoring a racing team in the 2021 Dakar Rally — the elite off-road endurance competition currently taking place in Saudi Arabia. The MyHeritage team comprises driver Danny Pearl, a veteran of off-road racing, and navigator Charly Gotlib, who has participated in the Dakar Rally more than 30 times over the years, and has received an honorary distinction of Dakar Legend from the race organizers. The team is managed by Omer Pearl, Danny’s son. In recent years, Omer has managed the Pearl Racing Team in different competitions around the world. The team is named the MyHeritage Team and is competing in the Dakar’s Lightweight Vehicle category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005542/en/
Trailblazing in the Arabian Desert: MyHeritage Sponsors Team Competing in 2021 Dakar Rally (Photo: Business Wire)
As the international market leader for exploring family history and finding relatives, MyHeritage develops innovative search and matching technologies and has a global database of historical records to help millions of people connect to their family history. Sponsoring a team led by a father-son duo is par for the course for MyHeritage. The company has a long history of partnering with top athletes, sports teams, and cultural figures to reveal their family history, forge connections with their relatives, and underscore the importance of knowing one’s roots.
Danny and Omer Pearl founded the Pearl Racing Team out of their passion for motorsports. The team has competed for many years in the SSV category, racing in numerous international competitions.
The Dakar Rally is considered the toughest and most grueling off-road competition in the world. This is the second year the competition is being held in Saudi Arabia, following its relocation from South America, where it was held for the last decade. The race spans more than 7,000 kilometers and 12 days over the challenging and beautiful Saudi terrain. This year’s race departed from Jeddah and will traverse the entire Arabian desert in a circular course. Each day the team will navigate under the most extreme conditions, using a Road Book produced by the rally organizer.
“As leaders in the field of exploring and discovering family history, we are thrilled to support a team that includes a father and son who are competing in one of the world’s most difficult competitions,” said Gilad Japhet, Founder and CEO of MyHeritage. “Particularly during these challenging times, we appreciate the significance of supporting family members coming together in bold and creative ways, working as a team to achieve the impossible. Just like the Dakar, family history can be an enjoyable and adventurous journey.”
“It is with great pride and excitement that we enter this legendary race,” said Omer Pearl. “We believe that determination and perseverance yield results, and our family bond is one of the driving forces behind our success. We hope that our efforts will inspire more families to team up and work together to pursue their dreams.”
The Dakar Rally is taking place between January 3–15, 2021.
About MyHeritage
MyHeritage is the leading global discovery platform for exploring family history. With billions of historical records and family tree profiles, and with sophisticated matching technologies that work across all its assets, MyHeritage allows users to discover their past and empower their future. Launched in 2016, MyHeritage DNA has become one of the world’s largest consumer DNA databases, with more than 4.6 million customers. Since 2020, MyHeritage is home to the world’s best technologies for enhancing and colorizing historical photos. MyHeritage is the most popular DNA test and family history service in Europe. www.myheritage.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005542/en/
Contact information
MyHeritage
Rafi Mendelsohn
Director of PR & Social Media
Phone: 917-725-5018
Email: pr@myheritage.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom